Rate of progression differs in frontotemporal dementia and Alzheimer disease.
OBJECTIVE
To compare survival and rates of cognitive and functional decline in patients with autopsy-confirmed frontotemporal dementia (FTD) and Alzheimer disease (AD) in a large multicenter study.


BACKGROUND
Despite advances in the clinical characterization of FTD, little is known about its rate of progression. Characterizing survival and rate of decline in FTD is important because it can provide prognostic guidelines and benchmarks to use in the evaluation of disease-modifying drugs.


METHODS
Seventy patients with FTD and 70 patients with AD who were followed by seven Alzheimer disease research centers until confirmation of diagnosis at autopsy were matched for overall age, education, and Mini-Mental State Examination (MMSE) score at initial evaluation. Survival and rates of cognitive and functional decline were compared.


RESULTS
Patients with FTD had significantly shorter survival from initial evaluation to death than patients with AD (FTD = 4.2 years, AD = 6.0 years; log-rank test = 5.17, p < 0.05), and they declined significantly faster over one year on the MMSE (mean annual rate of change: -6.7 points for FTD vs -2.3 points for AD). A significantly greater proportion of patients with FTD were impaired in basic activities of daily living (ADLs) at initial evaluation, and lost the capacity for independent or minimally-assisted ADLs over the subsequent year.


CONCLUSIONS
The results are consistent with shorter survival and faster rates of cognitive and functional decline in patients with frontotemporal dementia (FTD) compared to those with Alzheimer disease (AD). This suggests that FTD follows a more malignant disease course than AD once dementia is clinically recognized.
Rascovsky
K
K
University of California, San Diego, La Jolla, CA 92093-0948, USA.
Salmon
D P
DP
Lipton
A M
AM
Leverenz
J B
JB
DeCarli
C
C
Jagust
W J
WJ
Clark
C M
CM
Mendez
M F
MF
Tang-Wai
D F
DF
Graff-Radford
N R
NR
Galasko
D
D
D000203:Activities of Daily Living; D000328:Adult; D000367:Age Factors; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000473:pathology / Q000503:physiopathology* / Q000523:psychology; D003072:Cognition Disorders / Q000473:pathology / Q000503:physiopathology* / Q000523:psychology; D003704:Dementia / Q000473:pathology / Q000503:physiopathology* / Q000523:psychology; D018450:Disease Progression; D004522:Educational Status; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D011446:Prospective Studies; D017678:Sex Distribution; D015996:Survival Rate / Q000639:trends